Prof Brendan Wren Professor of Microbial Pathogenesis, London School of Hygiene & Tropical Medicine
The data on the Russian vaccine studies reported in the Lancet are encouraging - demonstrating the safety and immunogenicity of the adenovirus-based COVID-19 vaccines.
Polina Stepensky Chair of the Bone Marrow Transplantation and Cancer Immunotherapy Department at Hadassah hospital, Israel
First I should say to Russian scientists and Russian health professionals is ‘Bravo!’. This technology and scientific approach we perfectly understand and absolutely approve. You have made a real breakthrough in science and in medicine. We are really grateful that you have done a wonderful job. It is remarkable that stable humoral as well as cell-mediated immune response is generated. This is achieved through the use of two different vectors delivering the drug and, at the same time, solving the problem of a possible neutralizing effect on the second injection. The very high efficiency of two selected adenoviruses has been proven. Thus, the platform used by the Gamaleya Institute is the correct platform. The work done inspires great respect, and the vaccine itself is worthy of study and use.
Dr. Stephane Gayet Professor at Strasbourg University, doctor at Strasbourg University Hospital
This is a valuable and effective vaccine that I personally look forward to. I am very interested in the work that Russian researchers have done. I realized that one of the most advanced methods was being used - the adenoviral vector method.
Dr. Fabio Vilas-Boas Pinto Health Secretary of the State of Bahia
The Government of the State of Bahia, in Brazil, is very pleased with the agreement signed with the Sovereign Wealth Fund of the Russian Federation, which will guarantee access to the Sputnik V vaccine for the Brazilian people, as soon as it is approved by the Brazilian national regulatory authorities. As it is a vaccine built using human adenovirus, which is one of the safest and most effective vaccine development platforms in the world, we believe that the results of the ongoing phase 3 clinical trials will confirm the data observed in phases 1 and 2.
G V Prasad Co-Chairman and Managing Director of Dr. Reddy’s Laboratories
We are pleased to partner with RDIF to bring the vaccine to India. The Phase I and II results have shown promise, and we will be conducting Phase-III trials in India to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID 19 in India.
Shavkat Ismailov Chairman of LAXISAM Group of Companies
Cooperation on the Sputnik V vaccine with RDIF plays an important role. The vaccine was created by Russian scientists based on advanced scientific and clinical research.
Zhong Nanshan Director of the Guangzhou Institute of Respiratory Diseases, China
I am highly appraised the vaccine against COVID-19, developed by the Gamaleya Center. Let me congratulate your country on the completion of the state registration procedure. Russian adenoviral vaccine is safe and should successfully complete of its clinical trials.
Hildegund Ertl Professor, Vaccine & Immunotherapy Center at the Wistar Institute in Philadelphia, USA
From what I’ve seen out there, they are probably the most promising platform.
Ian Jones Virology professor at Reading University, United Kingdom
There is enough general background data on recombinant adenovirus-based vaccines to assume the vaccine itself will be safe at the usual doses.
Ashwani Mahajan National co-convener of Swadeshi Jagran Manch, India
Once the efficacy issue is resolved, then the cost would be an important issue. My feeling is that on both these accounts, the Russian vaccine would pass the test.
Message has been successfully sent!
